Nyxoah Announces Upcoming Investor Events

Core Insights - Nyxoah is a medical technology company focused on developing innovative treatments for Obstructive Sleep Apnea (OSA) [4] - The company will participate in several investor events in September 2025, including the Wells Fargo Healthcare Conference and the Morgan Stanley Annual Global Healthcare Conference [2][3] Company Overview - Nyxoah's primary product is the Genio system, which is a leadless and battery-free hypoglossal neurostimulation therapy for OSA, a condition linked to increased mortality and cardiovascular issues [4] - The Genio system received its European CE Mark in 2019 after the successful completion of the BLAST OSA study [5] - The company has completed two IPOs, one on Euronext Brussels in September 2020 and another on NASDAQ in July 2021 [5] - Following positive outcomes from the BETTER SLEEP study, Nyxoah expanded its therapeutic indications to include Complete Concentric Collapse (CCC) patients, which are currently contraindicated in competitors' therapies [5] - The company also announced positive results from the DREAM IDE pivotal study and received U.S. FDA approval for a Premarket Approval application in August 2025 [5]